|
Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
3
|
Resverlogix Corp.
|
Dec 02, 2019 02:42PM
|
|
Re: Resverlogix to present at Biotech Showcase in January
|
1
|
Resverlogix Corp.
|
Dec 09, 2016 10:06AM
|
|
Re: Resverlogix to present at Biotech Showcase in January
|
|
Resverlogix Corp.
|
Dec 14, 2016 03:58PM
|
|
Re: Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain
|
1
|
Resverlogix Corp.
|
May 31, 2017 09:52AM
|
|
Re: Resverlogix to Hold BETonMACE Conference Call and Webcast on November 18, 2019
|
2
|
Resverlogix Corp.
|
Nov 12, 2019 10:48AM
|
|
Re: Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018
|
3
|
Resverlogix Corp.
|
Aug 27, 2018 03:12PM
|
|
Re: Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018
|
7
|
Resverlogix Corp.
|
Aug 28, 2018 08:28AM
|
|
Re: Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018
|
2
|
Resverlogix Corp.
|
Aug 28, 2018 11:03AM
|
|
Re: Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018
|
6
|
Resverlogix Corp.
|
Aug 28, 2018 02:49PM
|
|
Re: Resverlogix Special Meeting Jun 30 9am MDT
|
1
|
Resverlogix Corp.
|
Jun 30, 2015 02:52PM
|
|
Re: Resverlogix Special Meeting Jun 30 9am MDT
|
3
|
Resverlogix Corp.
|
Jun 30, 2015 04:36PM
|
|
Re: Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial
|
7
|
Resverlogix Corp.
|
Feb 23, 2017 10:12AM
|
|
Re: Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
9
|
Resverlogix Corp.
|
Nov 02, 2020 07:56AM
|
|
Re: Resverlogix Repays $68.8 Million Loan
|
3
|
Resverlogix Corp.
|
Dec 07, 2017 02:52PM
|
|
Re: Resverlogix Repays $68.8 Million Loan
|
3
|
Resverlogix Corp.
|
Dec 07, 2017 03:14PM
|
|
Re: Resverlogix Repays $68.8 Million Loan
|
4
|
Resverlogix Corp.
|
Dec 06, 2017 07:52PM
|
|
Re: Resverlogix Receives US FDA Breakthrough Therapy Designation for Apabetalone
|
4
|
Resverlogix Corp.
|
Feb 03, 2020 09:20AM
|
|
Re: Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
|
8
|
Resverlogix Corp.
|
Jan 11, 2018 02:29PM
|
|
Re: Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial
|
5
|
Resverlogix Corp.
|
Aug 23, 2017 04:57PM
|
|
Re: Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial
|
5
|
Resverlogix Corp.
|
Jul 25, 2017 09:59AM
|
